Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Aus Klinik und Praxis / From Clinic and Practice

Erste Erfahrungen mit Amisulprid, einem in Deutschland neuen, atypischen Neuroleptikum in der Behandlung von Jugendlichen mit psychischen Erkrankungen

Aus Klinik und Praxis

Published Online:September 01, 2006https://doi.org/10.1024//1422-4917.29.3.230

Abstract

Zusammenfassung:Fragestellung: Neben den klassischen Neuroleptika finden bei Jugendlichen zunehmend atypische Neuroleptika zur Behandlung schizophrener und schizoaffektiver Psychosen Verwendung. Seit Beginn des Jahres 1999 ist in Deutschland in der Behandlung akuter schizophrener Psychosen ein neues, offensichtlich wirkungsvolles Neuroleptikum aus der Gruppe der Benzamide verfügbar: Amisulprid. Erste Erfahrungen mit der Anwendung von Amisulprid werden berichtet. Methode: Zehn gut dokumentierte Behandlungsverläufe bei Jugendlichen unter Behandlung mit Amisulprid werden hinsichtlich Effektivität, unerwünschter Wirkungen und Dosierung berichtet. Ergebnisse: Erste Erfahrungen im Einsatz von Amisulprid sind insbesondere wegen der erheblich günstigeren Nebenwirkungsprofile bei überzeugender antipsychotischer Wirksamkeit vielversprechend. Schlussfolgerungen: Amisulprid scheint bei solchen Jugendlichen eine geeignete pharmakotherapeutische Alternative zu sein, die ein erhöhtes Auftreten von Nebenwirkungen unter atypischer neuroleptischer Medikation zeigen. Kontrollierte Studien sind nötig, um die Effektivität und Sicherheit dieser Substanz auch im Jugendalter sicher einschätzen zu können.


Summary:Preliminary results using amisulpride, a novel, atypical neuroleptic in the treatment of adolescents with mental disorder

Objectives: In addition to conventional antipsychotic drugs, during the past decade an increasing number of atypical neuroleptics has been introduced in the treatment of juvenile schizophrenic and schizoaffective disorders. In 1999 Germany legalized the benzamide amisulpride for the treatment of acute and chronic schizophrenic symptoms. Preliminary treatment results are reported here. Methods: Ten adolescent cases are presented with regard to the efficacy, side effects and dosage of amisulpride. Results: Preliminary results on the use of amisulpride are promising. The rate of side effects is tolerable. Conclusions: Amisulprise seems to constitute a useful alternative in the treatment of juvenile schizophrenia for those who suffer from intolerable side effects of classical or atypical neuroleptics. Controlled studies are warranted to further clarify its efficacy and safety in the treatment of adolescents.

Literatur

  • Andreasen, N. The Scale for the Assessment of Negative Symptoms (SANS).. The University of Iowa, Iowa (1983a). First citation in articleGoogle Scholar

  • Andreasen, N. The Scale for the Assessment of Positive Symptoms (SAPS).. The University of Iowa, Iowa (1983b). First citation in articleGoogle Scholar

  • Boyer, P. , Lecrubier, Y. , Puech, A.J. , Dewailly, J. , Aubin, F. Treatment of negative symptoms in schizophrenia with amisulpride.. British Journal of Psychiatry, 166, 68– 72 (1995). First citation in articleCrossref Medline, Google Scholar

  • Boyer, P.; , Lecrubier, Y.; , Stalla-Bourdillon., A. , Fleurot, O. Amisulpride versus amineptine and placebo in the treatment of dysthymia.. Neuropsychobiology, 39, 25– 32 (1999). First citation in articleCrossref Medline, Google Scholar

  • Colonna, L. , Saleem, P. , Dondey-Nouvel, L. , Rein, W. the Amisulpride Study group Long-term safety of amisulpride in subchronic or chronic schizophrenia.. International Clinical Psychopharmacology, 15, 13– 22 (2000). First citation in articleCrossref Medline, Google Scholar

  • Coulouvrat, C. , Dondey-Nouvel, L. Safety of amisulpride (Solian®): a review of 11 clinical studies.. International Clinical Psychopharmacology, 14, 209– 218 (1999). First citation in articleCrossref Medline, Google Scholar

  • Cudennec, J.A. , Fage, D. , Benavides, J. , Scatton, B. Effects of amisulpride, an atypical antipsychotic, which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional activity in the rat.. Brain Research, 768, 257– 265 (1997). First citation in articleCrossref Medline, Google Scholar

  • Danion, J.M. , Rein, W. , Fleurot, O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride.. American Journal of Psychiatry, 156, 610– 616 (1999). First citation in articleMedline, Google Scholar

  • Dollfuss, S. , Petit, M. , Menard, J.F. , Lesieur, P. Amisulpride versus bromocriptine in infantile autism: A controlled crossover comparative study of two drugs with opposite effects on dopaminergic function.. Journal of Autism and Developmental Disorders, 22, 47– 60 (1992). First citation in articleCrossref Medline, Google Scholar

  • Kay, S.R. , Fiszbein, A. , Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia.. Schizophrenia Bulletin, 13, 261– 276 (1987). First citation in articleCrossref Medline, Google Scholar

  • Lecrubier, Y. , Boyer, P. , Turjanski, S. , Rein, W. Amisulpride versus imipramine and placebo in dysthymia and major depression.. Journal of Affective Disorders, 43, 95– 103 (1997). First citation in articleCrossref Medline, Google Scholar

  • Loo, H. , Poirier-Littre, M.F. , Theron, M. , Rein, W. , Fleurot, O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.. British Journal of Psychiatry, 170, 18– 22 (1997). First citation in articleCrossref Medline, Google Scholar

  • Möller, H.J. , Boyer, P. , Fleurot, O. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol.. Psychopharmacology, 132, 396– 401 (1997). First citation in articleCrossref Medline, Google Scholar

  • Overall, J.F. , Gorham, D.R. The Brief Psychiatric Rating Scale.. Psychology Report, 10, 799– 812 (1962). First citation in articleGoogle Scholar

  • Paillere-Martinot, M.L. , Lecrubier, Y. , Martinot, J.L. , Aubin, F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.. American Journal of Psychiatry, 152, 130– 133 (1995). First citation in articleCrossref Medline, Google Scholar

  • Peters, D.H. , Faulds, D. Tiapride.. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs, 47, 1010– 1032 (1994). First citation in articleGoogle Scholar

  • Peuskens, J. , Bech, P. , Möller, H.J. , Bale, R. , Fleurot, O. , Rein, W. Amisulpride versus Risperidone in the treatment of acute exacerbations of schizophrenia.. Psychiatry Research, 88, 107– 117 (1999). First citation in articleCrossref Medline, Google Scholar

  • Puech, A.J. , Fleurot, O. , Rein, W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. Haloperidol.. Acta Psychiatrica Scandinavica, 98, 65– 72 (1998). First citation in articleCrossref Medline, Google Scholar

  • Ravizza, L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety versus amitryptiline.. Journal of Psychopharmacology, 13, 248– 254 (1999). First citation in articleCrossref Medline, Google Scholar

  • Remschmidt, H. , Schulz, E. , Martin, M. An open trial of clozapine in thirty-six adolescents with schizophrenia.. Journal of Child and Adolescent Psychopharmacology, 4, 31– 41 (1994). First citation in articleCrossref, Google Scholar

  • Remschmidt, H. , Hennighausen, K. , Clement, H.W. , Heiser, P. , Schulz, E. Atypische Neuroleptika in der Kinder- und Jugendpsychiatrie.. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 28, 45– 57 (2000). First citation in articleLink, Google Scholar

  • Scatton, B. , Claustre, Y. , Cudennec, A. , Oblin, A. , Perrault, G. , Sanger, D.J. , Schoemaker, H. Amisulpride: from animal pharmacology to therapeutic action.. International Clinical Psychopharmacology, 12 Suppl. 2, 29– 36 (1997). First citation in articleCrossref, Google Scholar

  • Schoemaker, H. , Claustre, Y. , Fage, D. , Rouquier, L. , Chergui, K. , Curet, O. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.. Journal of Pharmacology and Experimental Therapy, 280, 83– 97 (1997). First citation in articleMedline, Google Scholar

  • Speller, J.C. , Barnes, T.R.E. , Curson, D.A. One-year low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms.. British Journal of Psychiatry, 171, 564– 568 (1997). First citation in articleCrossref Medline, Google Scholar

  • Tridon, P. Essai clinique de l'amisulpride en neuropsychiatrie infantile.. Neuropsychiatrie de l'Enfance, 37, 89– 91 (1989). First citation in articleGoogle Scholar

  • Toren, P. , Laor, N. , Weizman, A. Use of atypical neuroleptics in child and adolescent psychiatry.. Journal of Clinical Psychiatry, 59, 644– 656 (1998). First citation in articleCrossref Medline, Google Scholar

  • Trillet, M. , Moreau, T. , Dalery, J. , de Villard, R. , Aimard, G. Traitement de la maladie de Gilles de la Tourette par l'amisulpride (Brief).. Presse Médecine, 19, 175– 175 (1990). First citation in articleMedline, Google Scholar

  • Wetzel, H. , Phillipp, M. , Hillert, A. , Gattaz, W.F. , Sauer, H. , Adler, G. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist.. Psychopharmacology, 137, 223– 232 (1998). First citation in articleCrossref Medline, Google Scholar

  • World Health Organization/WHO Hrsg. Internationale Klassifikation psychischer Störungen (ICD-10).. Deutsche Bearbeitung von Dilling, H.; Mombour, W.; Schmidt, M.H. Huber, Bern (1993). First citation in articleGoogle Scholar